1. Definition, epidemiology and etiopathogenesis
2. Clinical features (mucocutaneous, musculoskeletal, renal, neuropsychiatric, cardiopulmonary, hematologic)
3. Diagnosis and classification criteria (ACR/EULAR 2019, SLICC), autoantibodies and labs
4. Lupus nephritis (ISN/RPS classes)
5. Modern management (hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, flares, pregnancy)
6. Ayurvedic correlation (disease concepts, dosha and dhatu involvement, samprapti)
7. Ayurvedic treatment (shodhana, shamana, single drugs, formulations, pathya-apathya, integrative approach)

• Amavata and Vata-rakta, for the joint and systemic inflammation.
• Rakta-pradoshaja vikara or Pitta-pradhana tridoshaja vyadhi, for the rash, photosensitivity and fever.
• Ojo-vyapad (ojakshaya or vishrimsa), for the immune dysregulation.
• Dushi visha and Gara visha, for the chronic, relapsing, toxin-driven course.

• Deepana-pachana and Amapachana.
• Shodhana, such as mild virechana and basti, where the patient is strong enough.
• Shamana drugs such as Guduchi, Amalaki, Haridra, Manjishtha, Sariva, Kaishora guggulu and Mahatiktaka ghrita.
• Rasayana for Ojas.
• Pathya-apathya, meaning diet and lifestyle (for example, avoiding sun and hot, spicy, sour foods).

1. Definition, epidemiology and etiopathogenesis
2. Clinical features (mucocutaneous, musculoskeletal, renal, neuropsychiatric, cardiopulmonary, hematologic)
3. Diagnosis and classification criteria (ACR/EULAR 2019, SLICC), autoantibodies and labs
4. Lupus nephritis (ISN/RPS classes)
5. Modern management (hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, flares, pregnancy)
6. Ayurvedic correlation (disease concepts, dosha and dhatu involvement, samprapti)
7. Ayurvedic treatment (shodhana, shamana, single drugs, formulations, pathya-apathya, integrative approach)

• Amavata and Vata-rakta, for the joint and systemic inflammation.
• Rakta-pradoshaja vikara or Pitta-pradhana tridoshaja vyadhi, for the rash, photosensitivity and fever.
• Ojo-vyapad (ojakshaya or vishrimsa), for the immune dysregulation.
• Dushi visha and Gara visha, for the chronic, relapsing, toxin-driven course.

• Deepana-pachana and Amapachana.
• Shodhana, such as mild virechana and basti, where the patient is strong enough.
• Shamana drugs such as Guduchi, Amalaki, Haridra, Manjishtha, Sariva, Kaishora guggulu and Mahatiktaka ghrita.
• Rasayana for Ojas.
• Pathya-apathya, meaning diet and lifestyle (for example, avoiding sun and hot, spicy, sour foods).

1. Definition, epidemiology and etiopathogenesis
2. Clinical features (mucocutaneous, musculoskeletal, renal, neuro-psychiatric, cardiopulmonary, hematologic)
3. Diagnosis: ACR/EULAR 2019 criteria, autoantibodies, complement and disease activity scores
4. Lupus nephritis (ISN/RPS classes)
5. Modern management (hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, flares, pregnancy)
6. Ayurvedic correlation (disease concepts, doshas, dhatus, samprapti)
7. Ayurvedic treatment (shodhana, shamana, single drugs, formulations, pathya-apathya, integrative approach)

• Amavata and Vata-rakta, for the joint and systemic inflammation.
• Rakta-pradoshaja vikara or Pitta-pradhana tridoshaja vyadhi, for the rash, photosensitivity and fever.
• Ojo-vyapad (ojakshaya or vishrimsa), for the immune dysregulation.
• Dushi visha or Gara visha, for the chronic, relapsing, toxin-driven course.

• Deepana-pachana to clear ama.
• Shodhana (mild virechana, basti) where the patient is strong enough.
• Shamana drugs such as Guduchi, Amalaki, Haridra, Manjishtha, Sariva, Kaishora guggulu and Mahatiktaka ghrita.
• Rasayana for Ojas.
• Pathya-apathya, meaning diet and lifestyle, including sun avoidance and avoiding hot, spicy and sour foods.

1. Definition, epidemiology and etiopathogenesis
2. Clinical features (mucocutaneous, musculoskeletal, renal, neuropsychiatric, cardiopulmonary, hematologic)
3. Diagnosis and classification criteria (ACR/EULAR 2019, SLICC), autoantibodies and labs
4. Lupus nephritis (ISN/RPS classes)
5. Modern management (hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, flares, pregnancy)
6. Ayurvedic correlation (disease concepts, dosha and dhatu involvement, samprapti)
7. Ayurvedic treatment (shodhana, shamana, single drugs, formulations, pathya-apathya, integrative approach)

• Amavata and Vata-rakta, for the joint and systemic inflammation.
• Rakta-pradoshaja vikara or Pitta-pradhana tridoshaja vyadhi, for the rash, photosensitivity and fever.
• Ojo-vyapad (ojakshaya or vishrimsa), for the immune dysregulation.
• Dushi visha and Gara visha, for the chronic, relapsing, toxin-driven course.

• Deepana-pachana and Amapachana.
• Shodhana, such as mild virechana and basti, where the patient is strong enough.
• Shamana drugs such as Guduchi, Amalaki, Haridra, Manjishtha, Sariva, Kaishora guggulu and Mahatiktaka ghrita.
• Rasayana for Ojas.
• Pathya-apathya, meaning diet and lifestyle (for example, avoiding sun and hot, spicy, sour foods).

1. Definition, epidemiology and etiopathogenesis
2. Clinical features (mucocutaneous, musculoskeletal, renal, neuro-psychiatric, cardiopulmonary, hematologic)
3. Diagnosis: ACR/EULAR 2019 criteria, autoantibodies, complement and disease activity scores
4. Lupus nephritis (ISN/RPS classes)
5. Modern management (hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, flares, pregnancy)
6. Ayurvedic correlation (disease concepts, doshas, dhatus, samprapti)
7. Ayurvedic treatment (shodhana, shamana, single drugs, formulations, pathya-apathya, integrative approach)

• Amavata and Vata-rakta, for the joint and systemic inflammation.
• Rakta-pradoshaja vikara or Pitta-pradhana tridoshaja vyadhi, for the rash, photosensitivity and fever.
• Ojo-vyapad (ojakshaya or vishrimsa), for the immune dysregulation.
• Dushi visha or Gara visha, for the chronic, relapsing, toxin-driven course.

• Deepana-pachana to clear ama.
• Shodhana (mild virechana, basti) where the patient is strong enough.
• Shamana drugs such as Guduchi, Amalaki, Haridra, Manjishtha, Sariva, Kaishora guggulu and Mahatiktaka ghrita.
• Rasayana for Ojas.
• Pathya-apathya, meaning diet and lifestyle, including sun avoidance and avoiding hot, spicy and sour foods.

Systemic Lupus Erythematosus (SLE): Complete Notes with Ayurvedic Correlation and Treatment

1. Definition and epidemiology

• SLE is a chronic, relapsing-remitting, multisystem autoimmune disease. Autoantibodies and immune complexes cause inflammation and damage in many organs.
• It is classically a disease of women, with a female:male ratio of about 9:1. Onset is mostly between ages 15 and 45.
• It is more frequent and more severe in people of African, Hispanic and Asian ancestry. Men and children tend to have more severe disease, including more nephritis.
• Main causes of death: infection, lupus nephritis and renal failure, and accelerated atherosclerotic cardiovascular disease. Active CNS disease also contributes.

2. Etiopathogenesis

1. Defective clearance of apoptotic cells exposes nuclear antigens (nucleosomes, dsDNA, Sm, Ro, La).
2. Plasmacytoid dendritic cells produce type I interferon (the "interferon signature"), which activates the immune system.
3. Self-reactive B cells escape tolerance. BAFF/BLyS survival signals and T-cell help produce autoantibodies.
4. Immune complexes deposit in the glomeruli, skin and vessels. This activates the classical complement pathway, with consumption of C3 and C4.
5. Neutrophil extracellular traps (NETs) add more nuclear antigen.
6. Result: tissue injury, vasculitis, thrombosis (with antiphospholipid antibodies) and organ damage.

3. Clinical features

4. Diagnosis

4.1 Investigations

• CBC: cytopenias. ESR is raised, while CRP is often normal unless there is serositis or infection.
• Urine: protein, RBCs, cellular casts. Do a spot urine protein:creatinine ratio. Serum creatinine and eGFR. Kidney biopsy for any suspected nephritis.
• Direct Coombs, lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I.

• Complement: low C3, C4 and CH50 indicate activity.
• Activity scores: SLEDAI-2K, BILAG, SELENA-SLEDAI. Damage index: SLICC/ACR.

4.2 Classification criteria

• Entry criterion: ANA titer of at least 1:80 on HEp-2 cells.
• Then add weighted points across 10 domains (a clinical domain's highest-scoring item counts). Classify as SLE if the total is 10 or more and there is at least one clinical criterion.

4.3 Differential diagnosis

5. Lupus nephritis (ISN/RPS classification)

• Biopsy before treatment where possible. Add renoprotection: ACE inhibitor or ARB, blood pressure control, SGLT2 inhibitor where appropriate.
• Induction, class III/IV: glucocorticoids (pulse methylprednisolone, then a low-dose taper) plus mycophenolate or low-dose IV cyclophosphamide (Euro-Lupus: 500 mg every 2 weeks for 6 doses). For high-risk disease, add belimumab or a calcineurin inhibitor (voclosporin or tacrolimus).
• Maintenance: mycophenolate or azathioprine for at least 3 years. Taper steroids to 5 mg/day or less, or stop.
• Pure class V with nephrotic-range proteinuria: mycophenolate-based therapy.
• Refractory disease: rituximab, obinutuzumab (2025 update).
• Class VI and ESRD: dialysis or transplant. Lupus often quiets once on dialysis.

6. Modern management of SLE overall

6.1 Principles (EULAR 2023 update: 5 principles, 13 recommendations)

• The target is remission or low disease activity (LLDAS), with prevention of flares and organ damage.
• Use an SLE activity score at each visit.
• Hydroxychloroquine (HCQ) for all patients, at 5 mg/kg/day or less of real body weight. HCQ lowers flares, damage, thrombosis and mortality. Do baseline eye screening and annual screening after 5 years (earlier with renal impairment or higher doses). It is the only drug that can be continued in pregnancy without concern.
• Glucocorticoids as bridging only. Pulse methylprednisolone for severe flares. Long-term maintenance should be 5 mg/day prednisone equivalent or less, and withdrawn when possible.
• Immunosuppressants (methotrexate, azathioprine, mycophenolate) should be started early to control disease and spare steroids.
• Biologics: anifrolumab (type I interferon receptor antibody) and belimumab (anti-BLyS) in non-renal SLE that persists despite standard therapy. Rituximab for refractory disease. Cyclophosphamide for organ-threatening disease.

6.2 Organ-specific approach

6.3 Supportive care and general measures

• Sun protection (SPF 50 or higher), smoking cessation, exercise, vitamin D and calcium, and a bone-health plan if on steroids.
• Cardiovascular risk management: lipids, blood pressure, aspirin in selected patients.
• Vaccinations: inactivated vaccines (influenza, pneumococcal, HPV, recombinant zoster, COVID-19). Avoid live vaccines when on high-dose immunosuppression.
• Infection screening before immunosuppression (TB, hepatitis B and C).

6.4 Pregnancy

• Plan conception during quiescent disease (at least 6 months of remission).
• Continue HCQ. Add low-dose aspirin from about 12 weeks to lower pre-eclampsia risk.
• Safe options: azathioprine, tacrolimus, cyclosporine, low-dose prednisolone.
• Stop mycophenolate, cyclophosphamide, methotrexate and ACE inhibitors before conception.
• Anti-Ro/La positive mothers: fetal echocardiography surveillance and HCQ for prevention of congenital heart block.

6.5 Flares

6.6 Recent evidence check

• The 2023 EULAR update (PMID 37827694) and its systematic review (PMID 38777375). They support anifrolumab and belimumab in extrarenal SLE, and belimumab and voclosporin add-on in lupus nephritis.
• The 2025 EULAR kidney update (PMID 41107121). It adds obinutuzumab as an option.
• A 2026 network meta-analysis of interventions for SLE arthritis (PMID 42055851).

7. Ayurvedic correlation

7.1 Disease correlations

7.2 Nidana (causes)

7.3 Samprapti (pathogenesis)

1. Agnimandya leads to ama formation.
2. Nidana vitiates Pitta and Rakta. Vata is aggravated and obstructed (avarana) by vitiated Rakta (Raktavrita Vata) and ama.
3. This produces srotorodha, with Vata-Pitta-Rakta moving through the srotas and depositing in sites of khavaigunya (weakness). Sites: twak (skin), sandhi (joints), vrikka (kidneys), hridaya, majja.
4. Dhatu involvement: Rasa and Rakta first, then Mamsa, Asthi and Majja. Ojakshaya follows, which weakens vyadhikshamatva and perpetuates the process.
5. The chronic phase has a tridoshaja character with relapses and remissions.

8. Ayurvedic treatment

8.1 Principles

• Treatment follows Vatarakta and Amavata chikitsa, adjusted for dosha predominance and the patient's strength (bala).
• Nidana parivarjana: remove the causes (diet, sun exposure, stress, sleep).
• Langhana and Pachana for ama, then Snehana and Shodhana when the patient is strong enough, then Shamana and Rasayana (Ojas support).
• Shodhana should be done only in a stable phase, avoiding active flares, severe cytopenia, active nephritis with renal failure, or high-dose steroid cover without physician coordination.

8.2 Stage-wise plan

• Deepana-pachana: Trikatu, Panchakola, Chitrakadi vati, Shunthi (dry ginger) and Guduchi decoctions.
• Light diet (laghu ahara): mudga yusha, rice gruel, and warm water (kept lukewarm, not hot).
• Fever: Sudarshana ghana vati or churna, Guduchi, Amritottara kashaya.
• Rasna-based or Amruta-based kashayas (Rasnasaptaka, Amrutottara) for joints in the Amavata phase.

• Mridu virechana (mild purgation) is the main shodhana for Pitta-Rakta predominance. Example: Aragvadhadi avaleha or Avipattikara churna, Trivrit lehya, or Gandharvahastadi eranda taila, after snehana (internal Tiktaka ghrita or Mahatiktaka ghrita).
• Basti: for Vata predominance and joint disease. Ksheera basti with Dashamoola, Punarnavashtaka or Guduchi (as in the Ayurveda360 case report), or Tiktaka ksheera basti, Madhutailika basti, or Erandamuladi niruha. The Gururaja case combined Guduchi, Kaishora guggulu and basti.
• Raktamokshana (bloodletting, leech) is used in Vatarakta, but it is generally avoided in SLE because of anemia, thrombocytopenia and bleeding or thrombotic risk.
• External therapy: Pariseka or dhara with Pitta-Vata-shamaka dravyas (cold medicated milk or Kshirabala taila), Takradhara or Shirodhara for neuropsychiatric symptoms, Lepa with Chandana, Usheera or Yashtimadhu for rash, and Abhyanga with Chandanadi taila, Kshirabala taila or Pinda taila (avoid heat in a flare).

8.3 Pathya (wholesome) and apathya (unwholesome)

8.4 Reported outcomes and limits

• Case reports describe symptom relief (pain, swelling, rash, fatigue), ulcer healing, steroid dose reduction and no relapse over follow-up with Guduchi, Kaishora guggulu, mild virechana and basti-based regimens (Gururaja 2019, PMC6938929; Ayurveda360 2025 report; an IJDDT review also compiles several). These are uncontrolled single-patient or small observations, so they cannot show efficacy or safety.
• No randomized controlled trial of an Ayurvedic regimen in SLE has been found in my search.

8.5 Safety cautions (important)

• Do not replace HCQ, steroids or immunosuppressants. Taper steroids only under rheumatology supervision.
• Immunostimulant herbs (Guduchi, Ashwagandha) have a theoretical risk of aggravating autoimmunity. Reports of herb-induced liver injury, including autoimmune-hepatitis-like injury, have been described with Tinospora cordifolia. Monitor liver function.
• Guggulu preparations may affect the liver and interact with other drugs.
• Rasaushadhi and bhasma (metal-mineral preparations) carry a risk of heavy-metal contamination, kidney and liver toxicity. Use only well-tested, standardized products, especially in lupus nephritis.
• Turmeric (Haridra) and similar herbs may increase bleeding risk with anticoagulants or antiplatelet drugs.
• Pregnancy: avoid purgation and strongly acting herbs.
• Monitor CBC, LFT, RFT and urine regularly while combining therapies. Keep the rheumatologist and the Ayurvedic physician informed of everything the patient takes.

9. Integrative summary

1. SLE is diagnosed by the 2019 EULAR/ACR criteria (ANA at least 1:80 entry, 10 or more points). Anti-dsDNA and anti-Sm are the most specific antibodies. Low C3/C4 indicates activity.
2. HCQ for everyone, steroids as bridging only, and early steroid-sparing drugs. Belimumab and anifrolumab are used for persistent disease. Lupus nephritis needs a biopsy and mycophenolate or Euro-Lupus cyclophosphamide, with belimumab or voclosporin added in high-risk cases.
3. Ayurvedic correlation is mainly Vatarakta (Raktavrita Vata) with Amavata, Pitta-Rakta dushti and Ojakshaya. Treatment is staged: ama pachana, then mridu virechana and basti, then shamana and rasayana, with strict pathya. It supports but does not replace modern therapy.